Endovasc Announces Completion of LC/MS Assay by ABC Laboratories for Phase III Trial of Liprostin.

HOUSTON -- ENDOVASC INC. (OTCBB:EVSC), today announced that Analytical Bio-Chemical Laboratories, Inc. (ABC) has developed a highly sensitive High Performance Liquid Chromatography/Mass spectrophotometric assay (LC/MS) to detect prostaglandin E-1 (PGE-1) in the serum of patients treated with Liprostin.

Additionally, ABC has determined a method to separate free PGE-1 from encapsulated PGE-1, allowing direct measurement of the release rate of the drug from the liposome during and post-treatment of Liprostin in the patient. These methods will be used to conduct pharmacokinetic studies during Endovasc's Phase III trials.

Diane Dottavio, Ph.D., Endovasc's Chairman and Chief Executive Officer, commented, "ABC has provided us with a very important assay which will help us to determine the metabolic clearance rate of our drug, and perhaps answer questions regarding its mechanism of action and apparent 'long-acting' effect seen in our Phase II results."

Endovasc's Liprostin is a liposome-encapsulated form of prostaglandin E-1 (PGE-1) which is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent. In February 2006, Endovasc submitted its protocol for the phase IIIa clinical trial of Liprostin for treatment of intermittent claudication, a symptom of Peripheral Arterial Disease, to the FDA. Intermittent claudication causes a cramping sensation in the legs that is present during exercise or walking and occurs as a result of decreased blood and oxygen supply. If left untreated, clots may form and lead to leg ulcers, gangrene and ultimately amputation.

About Analytical Bio-Chemistry Laboratories, Inc.

Analytical Bio-Chemistry Laboratories, Inc. based in Columbia, MO, is a contract research and development company that provides analytical and biological services in support of U.S. and global product registrations for the pharmaceutical industry. Established in 1968, the company provides scientific consulting, custom synthesis, in-vitro/in-vivo services, pharmacokinetics, bio-analysis, and a full spectrum of cGMP analytical services. Through partnerships and industry alliances, ABC Labs provides unparalleled service and depth of experience that helps accelerate IND and NDA submissions and minimize time to market.

For more information please visit http://www.abclabs.com.

About Endovasc, Inc.

Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating through the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing a stent coating technology; and Nutraceutical Development Corporation. For more information about Endovasc, please visit www.endovasc.com.

Safe Harbor:

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.